A systematic review of semaglutide-associated kidney injury case reports
Abstract
Background: Although semaglutide is widely used due to its efficacy in glycemic control and weight reduction, cases of the associated adverse drug reactions (ADRs), including kidney injury, have gradually increased. This systematic review aimed to summarize reported cases and case series of semaglutide-associated renal injury and their clinical and laboratory features.
Methods: Case reports and case series on ADRs associated with semaglutide published in English and Chinese were systematically retrieved using relevant keywords from PubMed/MEDLINE, Web of Science, Embase, the Cochrane Library, and the Chinese National Knowledge Infrastructure (CNKI) database from database inception to October 31, 2025. Demographic characteristics, clinical information, ADRs, kidney-related laboratory tests, and outcomes were extracted. We used the Joanna Briggs Institute Critical Appraisal Checklist for Case Reports (JBI Case Report Checklist) to evaluate the quality of each included study.
Results: A total of 20 cases (7 males and 13 females) from 18 studies were included after screening 1039 selected publications, with patient ages ranging from 29 to 83 years. Most patients received semaglutide via subcutaneous injection for weight loss or blood sugar reduction. Except for one case with unknown history, all patients had a pre-existing medical condition and were receiving concomitant medications. ADRs occurred at the standard recommended dose, ranging from 0.25 to 2.0 mg and included acute…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 17 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.